Dr. Kropf is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
125 Queens Rd
Ste 600
Charlotte, NC 28204Phone+1 980-302-6600Fax+1 980-302-6605- Is this information wrong?
Education & Training
UPMC Medical EducationFellowship, Hematology and Medical Oncology, 2006 - 2009- UPMC Medical EducationResidency, Internal Medicine, 2003 - 2006
Georgetown University School of MedicineClass of 2003
Certifications & Licensure
NC State Medical License 2021 - 2025
PA State Medical License 2003 - 2021- American Board of Internal Medicine Hematology
Clinical Trials
- Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia Start of enrollment: 2012 Dec 13
- Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS Start of enrollment: 2013 Apr 01
- Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed Start of enrollment: 2016 Nov 02
- Join now to see all
Publications & Presentations
PubMed
- The effect of mobilizing large numbers of CD34 + cells (super-mobilizers) on the engraftment and survival in patients undergoing autologous stem cell transplantation.Jan S Moreb, Lori Lantos, Franklin Chen, Kathleen Elliott, James Dugan, Alan P Skarbnik, Patricia Lamont Kropf, Kimberly Ward> ;Transfusion and Apheresis Science. 2023 Dec 1
- 1 citationsGuadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study.Pierre Fenaux, Marco Gobbi, Patricia L Kropf, Jean-Pierre J Issa, Gail J Roboz, Jiri Mayer, Jürgen Krauter, Tadeusz Robak, Hagop Kantarjian, Jan Novak, Wieslaw W Jedrz...> ;Blood Advances. 2023 Sep 12
- 4 citationsSafety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine.Casey L O'Connell, Maria R Baer, Andreas Due Ørskov, Sunil Kumar Saini, Vu H Duong, Patricia Kropf, Jakob Werner Hansen, Denice Tsao-Wei, Hyo Sik Jang, Ashkan Emadi, S...> ;Clinical Cancer Research. 2022 Dec 15
- Join now to see all
Journal Articles
- Functional Genomic Landscape of Acute Myeloid LeukaemiaMarc M Loriaux, Christopher R Cogle, Patricia Kropf, Daniel A Pollyea, Uma Borate, Michael W Deininger, Nature
Lectures
- Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediat...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Phase I Results of a Multicenter Clinical Trial Combining Guadecitabine, a DNA Methyltransferase Inhibitor, with Atezolizumab, an Immune Checkpoint Inhibitor, in Patie...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Professional Memberships
- Member
Hospital Affiliations
Novant Health Presbyterian Medical CenterCharlotte, North Carolina
Novant Health Forsyth Medical CenterWinston Salem, North Carolina
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
